When is off-label off-road?

Por de Vries, E G E, Cherny, N I, Voest, E E
Publicado no Ann Oncol (2019)

When is off-label off-road?

Por de Vries, E G E, Cherny, N I, Voest, E E
Publicado no Ann Oncol (2019)

The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression

Por Houthuijzen, J M, Daenen, L G M, Roodhart, J M L, Voest, E E
Publicado em 2012

A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer

Por Molloy, T J, Devriese, L A, Helgason, H H, Bosma, A J, Hauptmann, M, Voest, E E, Schellens, J H M, van't Veer, L J
Publicado em 2011

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

Por Punt, C. J., Voest, E. E., Tueni, E., Van Oosterom, A. T., Backx, A., De Mulder, P. H., Hecquet, B., Lucas, C., Gerard, B., Bleiberg, H.
Publicado em 1997

Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells

Por te Velde, E A, Reijerkerk, A, Brandsma, D, Vogten, J M, Wu, Y, Kranenburg, O, Voest, E E, Gebbink, M, Borel Rinkes, I H M
Publicado em 2005

Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo.

Por Kuroki, M, Voest, E E, Amano, S, Beerepoot, L V, Takashima, S, Tolentino, M, Kim, R Y, Rohan, R M, Colby, K A, Yeo, K T, Adamis, A P
Publicado em 1996

Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer

Por Lalisang, R I, Voest, E E, Wils, J A, Nortier, J W, Erdkamp, F L, Hillen, H F, Wals, J, Schouten, H C, Blijham, G H
Publicado em 2000

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks

Por Kerbusch, T, Groenewegen, G, Mathôt, R A A, Herben, V M M, ten Bokkel Huinink, W W, Swart, M, Ambaum, B, Rosing, H, Jansen, S, Voest, E E, Beijnen, J H, Schellens, J H M
Publicado em 2004

Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study()(...

Por Snoeren, Nikol, van Hillegersberg, Richard, Schouten, Sander B., Bergman, Andre M., van Werkhoven, Erikv, Dalesio, Otilia, Tollenaar, Rob A.E.M., Verheul, Henk M., van der Sijp, Joost, Borel Rinkes, Inne H.M., Voest, E.E.
Publicado no Neoplasia (2017)

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy

Por Hannemann, J, Kristel, P, van Tinteren, H, Bontenbal, M, van Hoesel, Q G C M, Smit, W M, Nooij, M A, Voest, E E, van der Wall, E, Hupperets, P, de Vries, E G E, Rodenhuis, S, van de Vijver, M J
Publicado em 2006

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin

Por Ploquin, A, Olmos, D, Lacombe, D, A'Hern, R, Duhamel, A, Twelves, C, Marsoni, S, Morales-Barrera, R, Soria, J-C, Verweij, J, Voest, E E, Schöffski, P, Schellens, J H, Kramar, A, Kristeleit, R S, Arkenau, H-T, Kaye, S B, Penel, N
Publicado em 2012

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours

Por Kerklaan, B Milojkovic, Lolkema, M P J, Devriese, L A, Voest, E E, Nol-Boekel, A, Mergui-Roelvink, M, Langenberg, M, Mykulowycz, K, Stoebenau, J, Lane, S, Legenne, P, Wissel, P, Smith, D A, Giantonio, B J, Schellens, J H M, Witteveen, P O
Publicado no Br J Cancer (2015)

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

Por Lankheet, N A G, Kloth, J S L, Gadellaa-van Hooijdonk, C G M, Cirkel, G A, Mathijssen, R H J, Lolkema, M P J K, Schellens, J H M, Voest, E E, Sleijfer, S, de Jonge, M J A, Haanen, J B A G, Beijnen, J H, Huitema, A D R, Steeghs, N
Publicado em 2014